News

During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).

To address the potential medicines of tomorrow, a panel of experts will discuss emerging therapies and the potential of developing new medicines and repurposing old medicines on Tuesday Nov. 5, 2019 at CPhI in Frankfurt, Germany.

A recent report released by an FDA task force highlights the financial, manufacturing, and policy issues underlying the drug shortages of important prescription medicines in the United States.

The approval marks the first time a new glass composition has been approved by FDA since the approval of borosilicate glass more than 100 years ago.

The successful inspection comes after the facility passed a pre-approval inspection in June 2019 from Japan’s Pharmaceutical and Medical Device Agency for an innovative drug.

The company believes the investment will improve its support of clients’ research, development, and clinical manufacturing needs by expanding its development and manufacturing capacity.

The company will be exhibiting several solutions and innovations including its HarleNIR vision system, Yudoo software suite, and Ubiquity software.

The company will aim to increase its employee headcount to meet the demand for one-stop-shop drug products manufacturing services.

GE Healthcare Life Sciences’ KUBio box is an integrated, flexible biomanufacturing environment for viral vector-based gene therapies.

Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.

The company will showcase new solutions for isolation technology systems, sterilization, and pharmaceutical freeze-drying applications at the event.

The company is recalling Alprazolam Tablets, USP C-IV 0.5 mg because of potential presence of foreign substance.

US-based SP Industries acquired the sterile filling line assets of Spain-based i-Dositecno.

Gerresheimer enlarged a cleanroom, installed a high-performance furnace, and automated testing and packaging systems for pharmaceutical glass packaging in Essen, Germany.

The agency’s implementation of the SUPPORT Act has included new guidance documents and actions to restrict illicit drugs entering the US.

Phillips-Medisize, a Molex company, revealed its agreement with a biotechnology company to manufacture a wearable electronic-enabled combination product.

Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray.

Pfizer has issued a voluntary recall of batches of its docetaxel injection 80 mg/8 mL due to impurity concerns.

A second lawsuit has been filed by Centrient Pharmaceuticals India in the High Court of Delhi in New Delhi against Dalas Biotech for patent infringement.

A joint funding initiative, UKI2S Innovate Accelerator, has been providing funding for start-ups throughout the United Kingdom for 12 months.

Takeda Pharmaceutical Company has acquired an exclusive global license from COUR Pharmaceuticals for the development and commercialization of an investigational celiac disease therapy.

Sartorius has signed an agreement for the acquisition of parts of Danaher’s Life Science Portfolio in cash.

GE Healthcare has announced the inauguration of an open-access lab at the Mereside Campus of Alderley Park in the United Kingdom, which will be used to support acceleration of biotech, health, and life-sciences research.

Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance.

CHMP has recommended that Ervebo (rVSVΔG-ZEBOV-GP), a vaccine for active immunization against Ebola, be granted conditional marketing authorization in the EU.

AstraZeneca has committed to extending its Young Health Programme for a further five years (until 2025), spending $35 million to help educate young people on how to reduce the risks of non-communicable diseases.

CHMP has recommended that Baqsimi (glucagon), a non-injectable treatment for severe hypoglycemia, be granted marketing authorization in the EU.

The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging.

The new device can inject a range of drugs of different viscosities up to 35cP and different fill volumes up to 1mL.

The goal of the investment is for the cures to be made available across the globe, including in sub-Saharan Africa’s low-resource communities.